- Conditions
- Alcohol Use Disorder, Alcoholism
- Interventions
- XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
- Drug · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 1,743
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Failure
- Interventions
- Not listed
- Lead sponsor
- Kibow Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Brooklyn, New York
- Conditions
- Autism Spectrum Disorders
- Interventions
- Double blind phase Placebo Nasal Spray, double Blind Oxytocin Nasal Spray, Open Label intranasal oxytocin
- Drug
- Lead sponsor
- Linmarie Sikich
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New York, New York • White Plains, New York + 3 more
- Conditions
- Coronavirus Disease 2019
- Interventions
- Placebo, Leronlimab (700mg)
- Drug
- Lead sponsor
- CytoDyn, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
- Conditions
- Neoplasms, Brain
- Interventions
- Dabrafenib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more
- Conditions
- Graft Versus Host Disease
- Interventions
- Natalizumab, Methylprednisolone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasms, Breast
- Interventions
- lapatinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 5 more
- Conditions
- Solid Tumors
- Interventions
- Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
- Interventions
- Lanifibranor, Placebo
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Contact Lens Lubrication
- Interventions
- carboxymethylcellulose based eye drop formula, carboxymethylcellulose sodium based eye drop solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Bloomington, Illinois
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
- Interventions
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 15 Months
- Enrollment
- 852 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
- Conditions
- Healthy Female Volunteer
- Interventions
- D-0502
- Drug
- Lead sponsor
- InventisBio Co., Ltd
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Bipolar Disorder, Depression, Bipolar
- Interventions
- Ziprasidone, Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 60
- States / cities
- Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more
- Conditions
- Allergic Asthma
- Interventions
- Omalizumab, Placebo, Asthma therapies
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 17 Years to 70 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 100
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab, current formulation, Adalimumab, new formulation
- Biological
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Mesa, Arizona • Hemet, California • Wichita, Kansas + 3 more
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03, Computed Tomography, Zanzalintinib
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Bacterial Vaginosis
- Interventions
- SYM-1219
- Drug
- Lead sponsor
- Symbiomix Therapeutics
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more
- Conditions
- Prostate Cancer
- Interventions
- 99mTc-MIP-1404
- Drug
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Scar, Wound Healing
- Interventions
- SLI-F06
- Drug
- Lead sponsor
- Scarless Laboratories, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Encinitas, California • Austin, Texas
- Conditions
- Solid Tumors
- Interventions
- clofarabine (oral formulation)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Dallas, Texas • Tyler, Texas • Spokane, Washington
- Conditions
- Post Traumatic Stress Disorder, Traumatic Brain Injury
- Interventions
- Cannabidiol, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Peripheral Vascular Diseases
- Interventions
- riferminogene pecaplasmid, Placebo (for riferminogene pecaplasmid)
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Allergic Conjunctivitis
- Interventions
- Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
- Drug
- Lead sponsor
- Fovea Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas